Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03070145 · ClinicalTrials.gov registry record · NA

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

A NA study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT03070145 is a NA study of Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 13 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03070145, a NA study of Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

Conditions Studied

Interventions

  • OTHER Exercise Intervention

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2017-12-08
Est. Completion 2019-12-12
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT03070145

The ClinicalTrials.gov registry entry for NCT03070145 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise Intervention is the first listed.

NCT03070145 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03070145 about?

NCT03070145 is a clinical study titled "Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy". This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

What is the current status of trial NCT03070145?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-12-08. Estimated completion is 2019-12-12.

What conditions does trial NCT03070145 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03070145?

The interventions under investigation include: Exercise Intervention (OTHER).

Who is sponsoring clinical trial NCT03070145?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03070145 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.